COMPASS Pathways Dirección
Dirección controles de criterios 4/4
El CEO de COMPASS Pathways' es Kabir Nath , nombrado en Aug 2022, tiene una permanencia de 1.83 años. compensación anual total es $2.82M, compuesta por 21% salario y 79% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.038% de las acciones de la empresa, por valor de $166.82K. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 4 años, respectivamente.
Información clave
Kabir Nath
Chief Executive Officer (CEO)
US$2.8m
Compensación total
| Porcentaje del salario del CEO | 21.0% |
| Permanencia del CEO | 1.9yrs |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | 2.4yrs |
| Promedio de permanencia en la Junta Directiva | 4yrs |
Actualizaciones recientes de la dirección
Recent updates
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06
Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
Sep 15Compass Pathways: Huge Growth Potential, But I'm Cautious
Jun 04COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
May 25COMPASS Pathways raises $144M capital via equity offering
Apr 30COMPASS Pathways launches public offering
Apr 27We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate
Feb 08Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
Jan 01Compass Pathways: Risky And Overvalued
Dec 18What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?
Dec 18COMPASS Pathways: Risky But Can Pay Back Generously
Dec 14Compass Pathways: An Overvalued Psychedelic Company With A Single Mediocre Drug
Nov 23COMPASS Pathways ADS reports Q3 results
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$3m | US$595k | -US$118m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$102m |
| Mar 31 2023 | n/a | n/a | -US$95m |
| Dec 31 2022 | US$8m | US$243k | -US$92m |
Compensación vs. Mercado: La compensación total ($USD2.82M) de Kabir está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.44M).
Compensación vs. Ingresos: La compensación de Kabir ha sido consistente con los resultados de la empresa en el último año.
CEO
Kabir Nath (60 yo)
1.9yrs
Permanencia
US$2,824,758
Compensación
Mr. Kabir Kumar Nath M. A., M. B.A., is Chief Executive Officer and Director of COMPASS Pathways plc from August 1, 2022. He serves as President & CEO at Otsuka America Pharmaceutical, Inc. He served as Pr...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$2.82m | 0.038% $ 156.7k | |
| General Counsel & Chief Legal Officer | 2.4yrs | US$1.32m | 0.0059% $ 24.4k | |
| Chief Medical Officer | 3yrs | US$1.20m | 0.0029% $ 12.1k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | less than a year | sin datos | sin datos | |
| Chief Technology Officer | 2.5yrs | sin datos | sin datos | |
| Senior Vice President of Investor Relations | no data | sin datos | sin datos | |
| Chief Communications Officer | 1.8yrs | sin datos | sin datos | |
| Chief People Officer | no data | sin datos | sin datos | |
| Senior Advisor | 2.5yrs | sin datos | sin datos | |
| Chief Development Officer | 4.1yrs | sin datos | sin datos | |
| Advisor | no data | sin datos | sin datos | |
| Chief Research & Development Officer | less than a year | sin datos | sin datos |
2.4yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CMPS se considera experimentado (2.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$2.82m | 0.038% $ 156.7k | |
| Member of Scientific Advisory Network | no data | sin datos | sin datos | |
| Independent Non Executive Director | 3.8yrs | US$209.48k | 0% $ 0 | |
| Independent Chairman & Lead Independent Director | 6.2yrs | US$215.57k | 0.025% $ 105.0k | |
| Independent Director | less than a year | US$363.71k | 0% $ 0 | |
| Independent Non Executive Director | 4.3yrs | US$210.84k | 0% $ 0 | |
| Independent Non-Executive Director | 3.3yrs | US$200.86k | 0% $ 0 | |
| Independent Non-Executive Director | 6.2yrs | US$199.82k | 0.13% $ 537.9k | |
| Independent Non-Executive Director | 6.2yrs | US$214.78k | 0.049% $ 202.7k | |
| Member of Scientific Advisory Network | no data | sin datos | sin datos | |
| Member of Scientific Advisory Network | no data | sin datos | sin datos | |
| Special Advisor of Patient Experience | no data | sin datos | sin datos |
4.0yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de CMPS se considera experimentada (4 años de antigüedad promedio).